Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Coherus Oncology (Nasdaq: CHRS) will release first quarter 2026 financial results after market close on Monday, May 11, 2026.

Rhea-AI Summary

Coherus Oncology (Nasdaq: CHRS) will release first quarter 2026 financial results after market close on Monday, May 11, 2026.

The company will host a management conference call and webcast starting at 5:00 p.m. Eastern Time on May 11, 2026. A replay and press release will be available at https://investors.coherus.com.

Argus May 4 session

-3.89% close to close Open Argus

Details

News Market Reaction – CHRS

On May 4, the day this news came out, CHRS closed 3.89% below the previous close.

Data tracked by StockTitan Argus for the May 4 session.

Market Context

This announcement schedules Coherus Oncology’s Q1 2026 financial results for release after market cl...

Analysis

This announcement schedules Coherus Oncology’s Q1 2026 financial results for release after market close on May 11, 2026, followed by a 5:00 p.m. ET conference call and webcast. It mirrors the company’s prior practice of pairing earnings with management commentary and online access. Investors may focus on how upcoming results build on previously reported 2025 performance and capital raises, while monitoring future filings and event updates for additional context.

Key Figures

Earnings release date: May 11, 2026 Conference call time: 5:00 p.m. Eastern Time Publication date: May 4, 2026

Earnings release date

May 11, 2026

Scheduled Q1 2026 financial results release after market close

Conference call time

5:00 p.m. Eastern Time

Start time for Q1 2026 results call on May 11, 2026

Publication date

May 4, 2026

Announcement date for Q1 2026 earnings release schedule

Previous Earnings date Reports

1 past event · Latest: Mar 02

Same Type 1 event

1. Mar 02

   Earnings date notice

   24h Move

   -1.2%

   Announced date and time for full-year and Q4 2025 earnings release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

Regulation FD

1 terms

Regulation FD regulatory

"for complying with its disclosure obligations under Regulation FD."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, May 11, 2026, starting at 5:00 p.m. Eastern Standard Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI717266b2e2e943cb92bb04def907b571.

Webcast: https://edge.media-server.com/mmc/p/orxawzr2.

The press release with the first quarter 2026 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Please dial in15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI^® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:

Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Coherus Oncology (CHRS) release Q1 2026 results and what time is the conference call?

Coherus will release Q1 2026 results after market close on May 11, 2026, with a conference call starting at 5:00 p.m. ET. According to the company, management will discuss results and provide a general business update during the call.

How can investors access the Coherus Oncology (CHRS) May 11, 2026 earnings webcast and replay?

Investors can access the live webcast and replay at https://investors.coherus.com. According to the company, a live and archived webcast will be available on the Investors section following the conclusion of the conference call.

Is pre-registration required to join the Coherus Oncology (CHRS) May 11, 2026 conference call?

The company requests pre-registration to receive dial-in details and a personal PIN to access the live call. According to the company, attendees should pre-register via the provided registration link and dial in 15 minutes early.

Where will Coherus Oncology (CHRS) post the Q1 2026 press release and related materials?

The Q1 2026 press release and related materials will be posted at https://investors.coherus.com before the start of the conference call. According to the company, materials will be available on the Investors events and presentations page.

What time zone is used for the Coherus Oncology (CHRS) May 11, 2026 call and what should listeners know?

The call is scheduled for 5:00 p.m. Eastern Time on May 11, 2026; the notice uses Eastern Time for timing. According to the company, dial-in information is provided after pre-registration and listeners should join 15 minutes early.

Will Coherus Oncology (CHRS) use its investor website for disclosure of material information?

Yes, Coherus uses its investor website as a means of disclosing material non-public information and complying with Regulation FD. According to the company, investors should monitor https://investors.coherus.com for official releases and webcasts.